A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic
syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily
in patients with HPS. The primary endpoint is overall survival at two months.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center